Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559377 · ClinicalTrials.gov registry record · Phase 2
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00559377: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00559377 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00559377, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment for newly diagnosed stage 1B, stage II, stage II, or stage IV cervical cancer. Diagnostic procedures using positron emission tomography (PET scan), fluoromisonidazole F 18, and fludeoxyglucose F 18 to find oxygen in tumor cells may help doctors predict how patients will respond to treatment.
Interventions
- PROCEDURE positron emission tomography
- OTHER 18F-fluoromisonidazole
- RADIATION fluorodeoxyglucose F 18
- OTHER tissue oxygen measurement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00559377
The ClinicalTrials.gov registry entry for NCT00559377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which positron emission tomography is the first listed.
NCT00559377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00559377 about?
NCT00559377 is a clinical study titled "FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer". This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment for newly diagnosed stage 1B, stage II, stage II, or stage IV cervical cancer. Diagnostic procedures using positron emissio...
What is the current status of trial NCT00559377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-11. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00559377?
The interventions under investigation include: positron emission tomography (PROCEDURE), 18F-fluoromisonidazole (OTHER), fluorodeoxyglucose F 18 (RADIATION), tissue oxygen measurement (OTHER).
Who is sponsoring clinical trial NCT00559377?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.